The introduction and subsequent iterations of drug-eluting stent technologies have
substantially improved the efficacy and safety of percutaneous coronary interventions …

The scope of this focused update is limited to addressing recommendations on duration of
dual antiplatelet therapy (DAPT)(aspirin plus a P2Y12 inhibitor) in patients with coronary …

In-stent restenosis (ISR) remains the most common cause of stent failure after percutaneous
coronary intervention (PCI). Recent data suggest that ISR-PCI accounts for 5-10% of all PCI …

Background Percutaneous coronary intervention (PCI) with drug-eluting stents is the
standard of care for treatment of native coronary artery stenoses, but optimum treatment …

Objectives: This study sought to investigate the ischemic and bleeding outcomes of patients
fulfilling high bleeding risk (HBR) criteria who were randomized to zotarolimus-eluting …

A Cardiologia Intervencionista tem experimentado extraordinário avanço nos últimos anos,
sendo atualmente o método de revascularização do miocárdio mais empregado em todos …

The duration of dual antiplatelet therapy (DAPT) after coronary stenting has been evaluated
in randomized studies with apparently conflicting results. Although longer exposure …

Background Oxidation and inflammation play significant roles in the pathogenesis of
coronary artery diseases. Monocyte count to high-density lipoprotein (HDL) cholesterol ratio …

Background Antiplatelet agents are widely used to prevent cardiovascular events. The risks
and benefits of antiplatelet agents may be different in people with chronic kidney disease …

Objective Optimal duration of dual antiplatelet therapy (DAPT), defined as use of both aspirin
and a P2Y12 receptor inhibitor, after implantation of drug eluting stents (DES) is still subject …